Our initial focus at UNITY is on clearing senescent cells.
Cellular senescence is a biological “emergency brake” cells use to stop dividing. It’s an important anti-tumor mechanism, because it prevents cells from multiplying out of control. But after this “brake” has been pulled, senescent cells remain in the body, accumulating with age. And unlike normal cells, these cells secrete inflammatory molecules that harm neighboring cells and tissues.
UNITY has demonstrated in animal models that removing senescent cells reverses or prevents a wide range of diseases, including osteoarthritis, atherosclerosis, eye diseases, and kidney diseases.
At UNITY, we are creating senolytic medicines. These medicines target vulnerabilities unique to senescent cells, allowing us to clear them from the human body while leaving normal cells unaffected. We envision a future in which people get older without getting sicker — a future in which people stay healthy and mobile long into old age.
http://unitybiotechnology.com/
INPADOC patent family
METHODS AND COMPOSITIONS FOR KILLING SENESCENT CELLS AND FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS
Inventor(s):
LABERGE REMI-MARTIN [US]; CAMPISI JUDITH [US]; DAVALOS ALBERT [US]; DEMARIA MARCO [US]; DAVID NATHANIEL [US]; VASSEROT ALAIN PHILIPPE [US]; BAKER DARREN J [US]; CHILDS BENNETT G [US]; KIRKLAND JAMES L [US]; TCHKONIA TAMAR [US]; VAN DEURSEN JAN M A [US]; ZHU YI [US] +
Applicant(s):
BUCK INST FOR RES ON AGING [US]; UNITY BIOTECHNOLOGY INC [US]; MAYO FOUNDATION [US] +
Application number:
WO2015US13387 20150128
Priority number(s):
US201461932704P 20140128 ; US201461932711P 20140128 ; US201461979911P 20140415 ; US201462002709P 20140523 ; US201462042708P 20140827 ; US201462044664P 20140902 ; US201462057820P 20140930 ;US201462057825P 20140930 ; US201462057828P 20140930 ; US201462061627P 20141008 ; US201462061629P 20141008
Abstract of WO2015116740 (A1)
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
CLAIMS
1. A method for treating a senescence-associated disease or disorder comprising administering to a subject in need thereof a therapeutically-effective amount of a small molecule senolytic agent that selectively kills senescent cells over non- senescent cells; wherein the senescence-associated disease or disorder is not a cancer, wherein the senolytic agent is administered in at least two treatment cycles, wherein each treatment cycle independently comprises a treatment course of from 1 day to 3 months followed by a non-treatment interval of at least 2 weeks; provided that if the senolytic agent is an MDM2 inhibitor, the MDM2 inhibitor is administered as a monotherapy, and each treatment course is at least 5 days long during which the MDM2 inhibitor is administered on at least 5 days.
LINKh.
Inventor(s):
LABERGE REMI-MARTIN [US]; CAMPISI JUDITH [US]; DAVALOS ALBERT [US]; DEMARIA MARCO [US]; DAVID NATHANIEL [US]; VASSEROT ALAIN PHILIPPE [US]; BAKER DARREN J [US]; CHILDS BENNETT G [US]; KIRKLAND JAMES L [US]; TCHKONIA TAMAR [US]; VAN DEURSEN JAN M A [US]; ZHU YI [US] +
Applicant(s):
BUCK INST FOR RES ON AGING [US]; UNITY BIOTECHNOLOGY INC [US]; MAYO FOUNDATION [US] +
Application number:
WO2015US13387 20150128
Priority number(s):
US201461932704P 20140128 ; US201461932711P 20140128 ; US201461979911P 20140415 ; US201462002709P 20140523 ; US201462042708P 20140827 ; US201462044664P 20140902 ; US201462057820P 20140930 ;US201462057825P 20140930 ; US201462057828P 20140930 ; US201462061627P 20141008 ; US201462061629P 20141008
Abstract of WO2015116740 (A1)
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
CLAIMS
1. A method for treating a senescence-associated disease or disorder comprising administering to a subject in need thereof a therapeutically-effective amount of a small molecule senolytic agent that selectively kills senescent cells over non- senescent cells; wherein the senescence-associated disease or disorder is not a cancer, wherein the senolytic agent is administered in at least two treatment cycles, wherein each treatment cycle independently comprises a treatment course of from 1 day to 3 months followed by a non-treatment interval of at least 2 weeks; provided that if the senolytic agent is an MDM2 inhibitor, the MDM2 inhibitor is administered as a monotherapy, and each treatment course is at least 5 days long during which the MDM2 inhibitor is administered on at least 5 days.
LINKh.
(PULMONARY FIBROSIS SUCCESSFUL TREATMENT)
ReplyDeleteI'm from MaryLand USA, I was diagnosed with Pulmonary fibrosis in Feb 2011. I may have had it for 1 or 2 years prior to that. It started with a dry cough and mild temperature, shortness of breath and fatigue. A CT scan confirmed it and I was placed on prednisone (7.5 mg), azathioprine and N-Acetyl. As the disease progressed all medication stopped working, i was introduced to NewLife herbal clinic in South Africa who have successful herbal treatment to Pulmonary fibrosis and other lungs diseases. I spoke to few people who used the treatment here in USA and they all gave a positive response, so i immediately purchased the Pulmonary fibrosis herbal remedy and commenced usage, i used the herbal supplement for only 9 weeks, all symptoms gradually faded away, herbs are truly gift from God. contact this herbal clinic via their email (newlifeherbalclinic @ gmail. com or visit www. newlifeherbalclinic. weebly. com)
I was diagnosed with polymyositis in 2002 and idiopathic pulmonary fibrosis (IPF) by a lung biopsy in 2007. I have been on prednisone at various dosages from the beginning along with various immune suppressant medications. I began taking tacrolimus in 2008 and have held off any progression of more scarring. I had shortness of breath and coughing. I was relatively active but I learned to pace myself. I have the best medical team that all work together.. As the disease progressed all medication stopped working, i was introduced to Health herbal clinic in South Africa who have successful herbal treatment to Pulmonary fibrosis and other lungs diseases. I spoke to few people who used the treatment here in USA and they all gave a positive response, so i immediately purchased the Pulmonary fibrosis herbal remedy and commenced usage, i used the herbal supplement for only 9 weeks, all symptoms gradually faded away, herbs are truly gift from God. contact this herbal clinic via their email healthherbalclinic @ gmail. com or visit www. healthherbalclinic. weebly. com
ReplyDelete